159874-20-1

Basic information

• Product Name: 1-CBZ-4-(BOC-AMINO)PIPERIDINE
• Synonyms: 1-CBZ-4-(BOC-AMINO)PIPERIDINE;1-Benzyloxycarbonyl-4-tert-butoxycarbonylaMinopiperidine;1-Cbz-4-Boc-aMinopiperdine;4-[(tert-Butoxycarbonyl)amino]piperidine-1-carboxylic acid benzyl ester;Phenylmethyl 4-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]-1-piperidinecarboxylate;1-Piperidinecarboxylic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-, phenylmethyl ester;benzyl 4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate
• CAS NO: 159874-20-1
• Molecular Formula: C₁₈H₂₆N₂O₄
• Molecular Weight: 334.41004
• EINECS: -0
• Mol File: 159874-20-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 471.9±44.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.30±0.20(Predicted)
• CAS DataBase Reference: 1-CBZ-4-(BOC-AMINO)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CBZ-4-(BOC-AMINO)PIPERIDINE(159874-20-1)
• EPA Substance Registry System: 1-CBZ-4-(BOC-AMINO)PIPERIDINE(159874-20-1)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 159874-20-1(Hazardous Substances Data)

Usage

General Description

1-CBZ-4-(BOC-AMINO)PIPERIDINE is a complex chemical compound that is often used in scientific research and chemical reactions. It consists of various functional groups, including a carbobenzyloxy (Cbz) group, which is a type of protecting group used in organic chemistry, and a tert-butyloxycarbonyl (BOC) group, another protecting group for amines in chemical syntheses. 1-CBZ-4-(BOC-AMINO)PIPERIDINE features a piperidine ring, a common feature in many pharmaceutical drugs. Overall, it is highly valued in the field of chemistry for its versatility and distinctive reactive properties.

Upstream product

• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 220394-91-2 benzyl 4-isocyanatotetrahydro-1(2H)-pyridinecarboxylate 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 159874-37-0 4-(tert-butoxycarbonyl-ethyl-amino)-piperidine-1-carboxylic acid benzyl ester 
• 120278-07-1 benzyl 4-aminopiperidine-1-carboxylate 
• 221142-26-3 4-amino-piperidine-1-carboxylic acid benzyl ester trifluoroacetate 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 313977-45-6 tert-butyl N-ethyl-N-(4-piperidyl)carbamate 

Relevant articles and documents

Kinase inhibitor compounds

The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS

The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.